Promising ASX Penny Stocks For December 2024

In This Article:

As the Australian market navigates post-Christmas trading with thin volumes and cautious investor sentiment, attention turns to potential opportunities in overlooked sectors. Penny stocks, often associated with smaller or newer companies, offer a unique blend of affordability and growth potential. By focusing on those with strong financials and clear growth paths, investors can discover promising prospects within this segment of the market.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.765

A$140.36M

★★★★☆☆

LaserBond (ASX:LBL)

A$0.55

A$64.47M

★★★★★★

SHAPE Australia (ASX:SHA)

A$2.85

A$236.3M

★★★★★★

Helloworld Travel (ASX:HLO)

A$1.95

A$317.49M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.51

A$316.27M

★★★★★☆

Navigator Global Investments (ASX:NGI)

A$1.68

A$823.33M

★★★★★☆

EZZ Life Science Holdings (ASX:EZZ)

A$3.17

A$146.32M

★★★★★★

SKS Technologies Group (ASX:SKS)

A$1.59

A$199.48M

★★★★★★

Vita Life Sciences (ASX:VLS)

A$1.88

A$105.46M

★★★★★★

Servcorp (ASX:SRV)

A$4.87

A$480.5M

★★★★☆☆

Click here to see the full list of 1,054 stocks from our ASX Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Liontown Resources

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Liontown Resources Limited focuses on the exploration, evaluation, and development of mineral properties in Australia with a market cap of A$1.33 billion.

Operations: Liontown Resources Limited does not report any revenue segments.

Market Cap: A$1.33B

Liontown Resources Limited, with a market cap of A$1.33 billion, is pre-revenue and faces challenges typical of penny stocks. The company reported a net loss of A$64.92 million for the year ending June 30, 2024, with its auditor expressing doubts about its ability to continue as a going concern. Despite having sufficient short-term assets to cover liabilities and no significant shareholder dilution recently, Liontown's long-term liabilities exceed short-term assets by A$296.8 million. The management team is experienced but the board lacks tenure depth, and recent capital raises suggest ongoing financial restructuring efforts are underway.

ASX:LTR Financial Position Analysis as at Dec 2024
ASX:LTR Financial Position Analysis as at Dec 2024

PolyNovo

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally with a market cap of A$1.44 billion.